H.R. 909 · 114th Congress
Andrea Sloan CURE Act
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
McCaulSponsor10 cosponsors · 4 D, 6 R
R
Burgess
GK
D
Butterfield
HG
R
Griffith
LL
R
Lance
DM
D
Matsui
JF
R
Fortenberry
RH
R
Hanna
SP
D
Peters
TW
D
Walz
KC
R
Cramer5 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
Andrea Sloan Compassionate Use Reform and Enhancement Act or the Andrea Sloan CURE Act
What it does: CRS summary · Introduced in House · Feb 12, 2015
Andrea Sloan Compassionate Use Reform and Enhancement Act or the Andrea Sloan CURE Act
Amends the Federal Food, Drug, and Cosmetic Act to require the sponsor of an “investigational drug” (which is a drug that is designated as a breakthrough therapy, fast track product, infectious disease product, or drug for a rare disease or condition) to submit to the Food and Drug Administration (FDA) and make available to the public the sponsor's policy on requests for expanded access to the unapproved drug, including the minimum criteria for considering or approving requests and the time needed to make a decision.
Requires an investigational drug sponsor to explain a denied request for expanded access to the person who made the request.
Directs the Department of Health and Human Services to establish an Expanded Access Task Force. Requires the Task Force and the Government Accountability Office (GAO) to evaluate patient access to investigational drugs and make recommendations for improving access.
Directs the FDA to finalize the draft guidance entitled “Expanded Access to Investigational Drugs for Treatment Use--Qs & As,” taking into account reports from the Task Force and GAO.Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Andrea Sloan CURE Act
Also known as: Andrea Sloan Compassionate Use Reform and Enhancement Act
Latest action (Feb 13, 2015): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Feb 12, 2015
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.